Progressive myoclonus epilepsy of Unverricht-Lundborg type.
Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1) is characterized by onset at age 6-15 years, stimulus-sensitive myoclonus, tonic-clonic seizures, and typical EEG findings, with marked sensitivity to photic stimulation. Previously the course of the disease was progressive throughout the life, and no biochemical or pathologic marker existed for the diagnosis of EPM1. With modern anticonvulsive therapy, the prognosis has improved significantly, the symptoms are nowadays relatively well controlled, and the disease may not always progress. Moreover, the molecular genetic findings have now made possible an etiologic diagnosis of EPM1. The positional cloning strategy was applied to identify the gene whose defects are responsible for EPM1. The underlying gene encodes cystatin B, a cysteine protease inhibitor. The major mutation worldwide is an unstable expansion of a dodecamer minisatellite repeat unit in the promoter region of the cystatin B gene. In addition, five "minor" mutations have been described. Cystatin B mutations are now known to account for both Mediterranean myoclonus and for "Baltic" myoclonus, described mainly from Finland, thus solving a long-term controversy and proving that these two disorders are one single disease entity. The pathogenetic mechanisms in EPM1 are yet unknown, but in the majority of patients, a reduced level of the cystatin B gene product seems to be the primary mechanism in the pathology. Understanding the molecular pathogenesis of EPM1 may lead to the development of specific therapies for the disease.
Lehesjoki
A E
AE
Department of Medical Genetics, Haartman Institute, University of Helsinki, Finland. anna-elina.lehesjoki@helsinki.fi
Koskiniemi
M
M
D000293:Adolescent; D017668:Age of Onset; D002648:Child; D002874:Chromosome Mapping; D055313:Cystatin B; D015891:Cystatins / Q000235:genetics; D015853:Cysteine Proteinase Inhibitors / Q000235:genetics; D004569:Electroencephalography / Q000706:statistics & numerical data; D004831:Epilepsies, Myoclonic / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics*; D006801:Humans; D009154:Mutation; D015995:Prevalence; D014635:Valproic Acid / Q000627:therapeutic use
C524994:CSTB protein, human; D015891:Cystatins; D015853:Cysteine Proteinase Inhibitors; D014635:Valproic Acid; D055313:Cystatin B